2,355 results on '"Rosenfeld, M."'
Search Results
2. Development of a Diagnostic Approach Based on the Detection of Post-Translation Modifications of Fibrinogen Associated with Oxidative Stress by the Method of High Efficiency Liquid Chromatography
3. EPS4.07 Validation of home spirometry as a CF clinical trial endpoint: results of the OUTREACH study
4. P319 The impact of a whole foods dietary intervention on gastrointestinal (GI) symptoms, inflammation, and fecal microbiota in paediatric patients with cystic fibrosis: a pilot study
5. P236 Investigating the impact of elexacaftor/tezacaftor/ivacaftor therapy on longitudinal oropharyngeal microbiome dynamics in children with cystic fibrosis
6. Advancing Equity in Mobile Health Tools for Asthma: A Focus Group Study of Hispanic and Latinx Community Perspectives
7. Functional Role of Methionine Oxidation in Proteins: Arguments for and against
8. Effect of Hypochlorite- and Hydrogen Peroxide-Induced Oxidation of Fibrinogen on its Thermal Denaturation
9. Peroxide-Induced Damage to Plasminogen Molecules
10. Effect of Hypochlorite- and Peroxide-Induced Oxidation of Fibrinogen on the Fibrin Structure
11. Pediatric lung function testing during a pandemic: An international perspective
12. Hypochlorite-Induced Disturbance in the Secondary Structure of the Coagulation Factor XIII
13. The Nature of Resistance of the Coagulation Factor XIII Structure to Hypochlorite-Induced Oxidation
14. Oxidative Modification of Coagulation Factor XIII: Structural and Functional Aspects
15. The Structural–Functional Damage of Fibrinogen Oxidized by Hydrogen Peroxide
16. Multiscale Fluctuation Dynamics of Polymer Gels
17. Brain tumor epidemiology - A hub within multidisciplinary neuro-oncology. report on the 15th brain tumor epidemiology consortium (BTEC) annual meeting, Vienna, 2014
18. 607 Characteristics of individuals in the United States ineligible for ivacaftor and elexacaftor-tezacaftor-ivacaftor
19. 124 Is home spirometry accurate? Comparison between home and office spirometry in the PROMISE study
20. 540 Impact of elexacaftor-tezacaftor-ivacaftor on gastrointestinal outcomes, inflammation, exocrine pancreatic function, and fat malabsorption: Report of PROMISE PEDS GI
21. 141 Factors associated with significantly corrected sweat chloride in people with cystic fibrosis taking elexacaftor-tezacaftor-ivacaftor—results from the PROMISE and RECOVER studies
22. 112 The lung clearance index to inform clinical decision-making in early cystic fibrosis lung disease: findings from a prospective study
23. 513 Effect of CFTR modulator treatment on digestive disorders: analysis of ivacaftor licensing in the U.K. and U.S. cystic fibrosis registries
24. 118 Research coordination perceptions of a coached home spirometry protocol: ongoing experiences with the OUTREACH study
25. Initial development and pilot testing of observer-reported outcomes (ObsROs) for children with cystic fibrosis ages 0–11 years
26. Longitudinal development of initial, chronic and mucoid Pseudomonas aeruginosa infection in young children with cystic fibrosis
27. 123 Home spirometry as a cystic fibrosis clinical trial endpoint: results of the OUTREACH Study.
28. Hypochlorite-Induced Damage of Plasminogen Molecules: Structural-Functional Disturbance
29. Peroxide-Induced Oxidative Modification of Hemoglobin
30. Hypochlorite-Induced Oxidative Modification of Fibrinogen
31. EPS5.02 Faecal microbiota changes in patients with cystic fibrosis with 6 months of elexacaftor/tezacaftor/ivacaftor: preliminary findings from the PROMISE study
32. Asthma Characteristics and Allergic Sensitization Among Adolescents With HIV and HIV-uninfected Adolescents in Nairobi, Kenya
33. Inclusivity of the North American Primary Ciliary Dyskinesia (PCD) Foundation Clinical Registry
34. Long-term Exposure to Air Pollution and Lung Function in Cystic Fibrosis
35. Airway Disease Progression on Chest Computed Tomography in Children With Primary Ciliary Dyskinesia
36. Evaluating a Mobile Health Tool to Guide Management of Acute Pediatric Respiratory Illnesses: A Pilot Feasibility Study in 2 Ugandan Primary Care Health Centers
37. Association of meteorological and geographical factors and risk of initial Pseudomonas aeruginosa acquisition in young children with cystic fibrosis
38. The Transcription Factor KLF2 Restrains CD4+ T Follicular Helper Cell Differentiation
39. Study of Human Fibrinogen Oxidative Modification using Differential Scanning Calorimetry
40. Oxidation-induced modification of the fibrinogen polypeptide chains
41. Modification of human serum albumin under induced oxidation
42. Modification of the catalytic subunit of plasma fibrin-stabilizing factor under induced oxidation
43. 548 Locus near ICOS is genetic modifier for risk of Mycobacterium avium complex airway infection in persons with cystic fibrosis
44. 213 Composition of fecal microbiota and bile acid abundances with 1 month of elexacaftor/tezacaftor/ivacaftor in pediatric patients with cystic fibrosis: Preliminary findings from PROMISE Pediatrics Study
45. 224 Elexacaftor/tezacaftor/ivacaftor alters gastrointestinal symptoms and inflammation: Report of PROMISE Pediatric Gastrointestinal Study
46. 119 Pulmonary exacerbation antibiotic treatment for children with cystic fibrosis and polymicrobial infection
47. 41 Association between Pseudomonas aeruginosa infection stage and lung function trajectory in children with cystic fibrosis
48. 4 Role of hyperglycemia in cystic fibrosis pulmonary exacerbations
49. 173 Effectiveness of elexacaftor/tezacaftor/ivacaftor in children with cystic fibrosis: The pediatric PROMISE study
50. 182 A qualitative needs assessment of people with cystic fibrosis and research coordinators to inform future clinical trials incorporating home spirometry as an endpoint
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.